The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats

Brain Research

Volumn 1363, Issue , 2010, Pages 40-48

  Walsh, Sinéad ^a   Gorman, Adrienne M ^a   Finn, David P ^a   Dowd, Eilís ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

6 Hydroxydopamine; Dyskinesia; Endocannabinoid system; Levodopa; Parkinson's disease

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BENSERAZIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; DEXANABINOL; ENDOCANNABINOID; LEVODOPA; OXIDOPAMINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MOTOR CONTROL; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; PARKINSONIAN DISORDERS; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

RATTUS;

EID: 78149471067     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.09.086     Document Type: Article

References (52)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 3 2001 448 458
2. T. Antonelli, M.C. Tomasini, M. Tattoli, T. Cassano, S. Finetti, E. Mazzoni, L. Trabace, M.R. Carratu, V. Cuomo, S. Tanganelli, and L. Ferraro Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 and carbon monoxide reduces extracellular glutamate levels in primary rat cerebral cortex cell cultures Neurochem. Int. 49 6 2006 568 576
3. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells Mol. Pharmacol. 63 4 2003 908 914
4. W. Birkmayer, and O. Hornykiewicz The effect of l-3,4- dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism Parkinsonism Relat. Disord. 4 2 1998 59 60
5. J.M. Brotchie Nondopaminergic mechanisms in levodopa-induced dyskinesia Mov. Disord. 20 8 2005 919 931
6. X. Cao, L. Liang, J.R. Hadcock, P.A. Iredale, D.A. Griffith, F.S. Menniti, S. Factor, J.T. Greenamyre, and S.M. Papa Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys J. Pharmacol. Exp. Ther. 323 1 2007 318 326
7. M. Carta, H.S. Lindgren, M. Lundblad, R. Stancampiano, F. Fadda, and M.A. Cenci Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats J. Neurochem. 96 6 2006 1718 1727
8. M. Carta, T. Carlsson, D. Kirik, and A. Bjorklund Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130 Pt 7 2007 1819 1833
9. M.A. Cenci, and H.S. Lindgren Advances in understanding L-DOPA-induced dyskinesia Curr. Opin. Neurobiol. 17 6 2007 665 671
10. M.A. Cenci, and M. Lundblad Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice Curr. Protoc. Neurosci. 2007 Chapter 9, Unit 9 25
11. T.N. Chase Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 50 5 Suppl 5 1998 S17 S25
12. T.J. De Vries, J.R. Homberg, R. Binnekade, H. Raaso, and A.N. Schoffelmeer Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats Psychopharmacology (Berl.) 168 1-2 2003 164 169
13. W.A. Devane, F.A. Dysarz III, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 34 5 1988 605 613
14. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 5090 1992 1946 1949
15. V. Di Marzo, M.P. Hill, T. Bisogno, A.R. Crossman, and J.M. Brotchie Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease FASEB J. 14 10 2000 1432 1438
16. E. Fernandez-Espejo, I. Caraballo, F. Rodriguez de Fonseca, B. Ferrer, F. El Banoua, J.A. Flores, and B. Galan-Rodriguez Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function Neuropsychopharmacology 29 6 2004 1134 1142
17. B. Ferrer, N. Asbrock, S. Kathuria, D. Piomelli, and A. Giuffrida Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias Eur. J. Neurosci. 18 6 2003 1607 1614
18. S.H. Fox, B. Henry, M. Hill, A. Crossman, and J. Brotchie Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 17 6 2002 1180 1187
19. 1 receptor in rat striatal neurons: a confocal microscopy study Synapse 53 3 2004 159 167
20. Y. Gilgun-Sherki, E. Melamed, R. Mechoulam, and D. Offen The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats Pharmacol. Toxicol. 93 2 2003 66 70
21. 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain J. Neural Transm. 110 11 2003 1279 1288
22. J.E. Kelsey, O. Harris, and J. Cassin The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease Behav. Brain Res. 203 2 2009 304 307
23. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 6 2009 1465 1476
24. M. Lundblad, S. af Bjerken, M.A. Cenci, F. Pomerleau, G.A. Gerhardt, and I. Stromberg Chronic intermittent L-DOPA treatment induces changes in dopamine release J. Neurochem. 108 4 2009 998 1008
25. M. Maccarrone, P. Gubellini, M. Bari, B. Picconi, N. Battista, D. Centonze, G. Bernardi, A. Finazzi-Agro, and P. Calabresi Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism J. Neurochem. 85 4 2003 1018 1025
26. J.P. Meschler, T.J. Conley, and A.C. Howlett Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity Pharmacol. Biochem. Behav. 67 3 2000 567 573
27. V. Mesnage, J.L. Houeto, A.M. Bonnet, I. Clavier, I. Arnulf, F. Cattelin, G. Le Fur, P. Damier, M.L. Welter, and Y. Agid Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease Clin. Neuropharmacol. 27 3 2004 108 110
28. T. Morera-Herreras, J.A. Ruiz-Ortega, A. Taupignon, J. Baufreton, I. Manuel, R. Rodriguez-Puertas, and L. Ugedo Regulation of subthalamic neuron activity by endocannabinoids Synapse 64 9 2010 682 698
29. M.G. Morgese, T. Cassano, V. Cuomo, and A. Giuffrida Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors Exp. Neurol. 208 1 2007 110 119
30. M.G. Morgese, T. Cassano, S. Gaetani, T. Macheda, L. Laconca, P. Dipasquale, L. Ferraro, T. Antonelli, V. Cuomo, and A. Giuffrida Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 Neurochem. Int. 54 1 2009 56 64
31. M. Olsson, G. Nikkhah, C. Bentlage, and A. Bjorklund Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test J. Neurosci. 15 5 Pt 2 1995 3863 3875
32. 1 cannabinoid receptors Neurobiol. Aging 2009 [Epub ahead of print]
33. R.G. Pertwee The pharmacology of cannabinoid receptors and their ligands: an overview Int. J. Obes. (Lond.) 30 Suppl 1 2006 S13 S18
34. B. Picconi, D. Centonze, K. Hakansson, G. Bernardi, P. Greengard, G. Fisone, M.A. Cenci, and P. Calabresi Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia Nat. Neurosci. 6 5 2003 501 506
35. A. Pisani, F. Fezza, S. Galati, N. Battista, S. Napolitano, A. Finazzi-Agro, G. Bernardi, L. Brusa, M. Pierantozzi, P. Stanzione, and M. Maccarrone High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients Ann. Neurol. 57 5 2005 777 779
36. 1 receptor antagonist, in diet-induced obese mice Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 2 2003 R345 R353
37. P.R. Sanberg, M.D. Bunsey, M. Giordano, and A.B. Norman The catalepsy test: its ups and downs Behav. Neurosci. 102 5 1988 748 759
38. M.C. Sanudo-Pena, K. Tsou, and J.M. Walker Motor actions of cannabinoids in the basal ganglia output nuclei Life Sci. 65 6-7 1999 703 713
39. M.C. Sanudo-Pena, J. Romero, G.E. Seale, J.J. Fernandez-Ruiz, and J.M. Walker Activational role of cannabinoids on movement Eur. J. Pharmacol. 391 3 2000 269 274
40. T. Schallert, S.M. Fleming, J.L. Leasure, J.L. Tillerson, and S.T. Bland CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury Neuropharmacology 39 5 2000 777 787
41. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol. Sci. 22 11 2001 565 572
42. 1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease Mov. Disord. 18 2 2003 138 149
43. K.M. Shaw, A.J. Lees, and G.M. Stern The impact of treatment with levodopa on Parkinson's disease Q. J. Med. 49 195 1980 283 293
44. K.A. Sieradzan, S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study Neurology 57 11 2001 2108 2111
45. M.V. Solbrig, R. Adrian, J. Baratta, D. Piomelli, and A. Giuffrida A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena Exp. Neurol. 194 2 2005 355 362
46. M. Steffens, B. Szabo, M. Klar, A. Rominger, J. Zentner, and T.J. Feuerstein Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex Neuroscience 120 2 2003 455 465
47. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 215 1 1995 89 97
48. M. van der Stelt, S.H. Fox, M. Hill, A.R. Crossman, S. Petrosino, V. Di Marzo, and J.M. Brotchie A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease FASEB J. 19 9 2005 1140 1142
49. 1 receptor expression in the 6-hydroxydopamine- induced nigrostriatal terminal lesion model of Parkinson's disease in the rat Brain Res. Bull. 81 6 2010 543 548
50. J.E. Westin, H.S. Lindgren, J. Gardi, J.R. Nyengaard, P. Brundin, P. Mohapel, and M.A. Cenci Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl- l-alanine-induced dyskinesia J. Neurosci. 26 37 2006 9448 9461
51. R.I. Wilson, and R.A. Nicoll Endocannabinoid signaling in the brain Science 296 5568 2002 678 682
52. 1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats Neurosci. Lett. 276 2 1999 71 74